Brief: Sight Sciences Announces First Patient Treated In Trident European Trial To Evaluate The Omni® Surgical System In Pseudophakic Eyes With Open-Angle Glaucoma
24/03/2022 20:44
March 24 (Reuters) - Sight Sciences Inc SGHT.O :
* SIGHT SCIENCES ANNOUNCES FIRST PATIENT TREATED IN TRIDENT
EUROPEAN TRIAL TO EVALUATE THE OMNI® SURGICAL SYSTEM IN
PSEUDOPHAKIC EYES WITH OPEN-ANGLE GLAUCOMA
Source text for Eikon: ID:nGNX6LjRXS
Further company coverage: SGHT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sight Sciences
See all newsSight Sciences, Inc. reports results for the quarter ended June 30 - Earnings Summary
Sight Sciences Q2 revenue rises 20%, beats estimates
Brief: Sight Sciences Q2 Revenue USD 23.4 Million Vs. IBES Estimate USD 21.7 Million
Sight Sciences, Inc. expected to post a loss of 15 cents a share - Earnings Preview
Sight Sciences raises FY 2026 revenue outlook